-
Press Release
Genesis Biotechnology Group Acquires BioBlocks to Grow the Preclinical Chemistry Services Portfolio of Genesis Drug Discovery & Development (GD3)
10/2021 -
Press Release
Genesis Drug Discovery & Development Appoints Anthony Rohr as Chief Operating Officer
9/2021 -
Press Release
Genesis Drug Discovery & Development Appoints Laura Sailor Veteran CRO Business Development Leader as Director of Business Development
9/2021 -
Press Release
Genesis Drug Discovery and Development acquires Integrated Analytical Solutions to add "off the shelf" PK profiling capabilities to its portfolio.
3/2021 -
Press Release
Genesis Drug Discovery and Development expands its presence in the clinical space by acquiring STATKING Clinical Services
1/2021 -
Press Release
Genesis Biotechnology Group announces second year of CRO relationship with Yale University
12/2020 -
Press Release
Genesis Biotechnology Group acquires Comparative Biosciences, Inc. (CBI) to add GLP Toxicology and Safety Pharmacology to its portfolio of Preclinical Services
8/2020 -
Press Release
Genesis Drug Discovery & Development (GD3) Announces Appointment of Anthony Rohr, as Chief Executive Officer of PharmOptima.
8/2020 -
Press Release
Genesis Biotechnology Group acquires NEDP to grow the Preclinical Chemistry services portfolio of Genesis Drug Discovery & Development
11/2019 -
Press Release
Genesis Drug Discovery & Development Expands Preclinical Contract Research Portfolio by Acquiring NexusPharma.
6/2019 -
Press Release
Genesis Drug Discovery & Development Announces Operating Agreement with Ophthy-DS, Inc.
2/2019 -
Press Release
Genesis Biotechnology Group announces partnership with Yale University
10/2018 -
Press Release
Genesis Biotechnology Group Expands Preclinical Contract Research Portfolio by Acquiring PharmOptima
3/2017